MSL
CORT icon

Mackay Shields LLC’s Corcept Therapeutics CORT Stock Holding History

Mackay Shields LLC’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-99,100
Closed -$2.36M – 837
2021
Q1 		$2.36M Sell
99,100
-65,500
-40% -$1.75M 0.02% 700
2020
Q4 		$4.31M Sell
164,600
-23,200
-12% -$489K 0.03% 535
2020
Q3 		$3.27M Sell
187,800
-23,500
-11% -$375K 0.02% 574
2020
Q2 		$3.55M Sell
211,300
-25,600
-11% -$360K 0.03% 515
2020
Q1 		$2.82M Sell
236,900
-16,300
-6% -$202K 0.03% 526
2019
Q4 		$3.06M Buy
+253,200
New +$3.52M 0.02% 701
2018
Q2 		– Sell
-49,300
Closed -$811K – 1219
2018
Q1 		$811K Buy
+49,300
New +$914K 0.01% 1026

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Mackay Shields LLC's CORT Position: Q2 2021 in Review

Mackay Shields LLC sold out of Corcept Therapeutics (CORT) in Q2 2021, closing a stake of 99,100 shares — an estimated $2.36M sold.

Mackay Shields LLC first reported a position in CORT in Q1 2018 and held it in 7 quarters. The position peaked at $4.31M in Q4 2020. 199 funds tracked by Wall St. Rank hold CORT as of Q2 2021.

  • Mackay Shields LLC reported no remaining Corcept Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 99,100 Corcept Therapeutics shares in Q2 2021, an estimated $2.36M.
  • Mackay Shields LLC first reported a position in Corcept Therapeutics in Q1 2018 and held it in 7 quarters.
  • Mackay Shields LLC's Corcept Therapeutics position peaked at $4.31M in Q4 2020.
  • 199 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.